{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T14:36:44Z","timestamp":1777473404640,"version":"3.51.4"},"reference-count":8,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2016,8,23]],"date-time":"2016-08-23T00:00:00Z","timestamp":1471910400000},"content-version":"vor","delay-in-days":22,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Internal Medicine Journal"],"published-print":{"date-parts":[[2016,8]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Off\u2010label use of rituximab in lupus nephritis is reported to be beneficial. While the optimal dose is unknown, the regimen of four intravenous doses of 375\u2009mg\/m<jats:sup>2<\/jats:sup> is commonly employed, despite expense and potential side\u2010effects.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>To investigate the response to single\u2010dose rituximab, added to standard corticosteroids plus additional immunosuppressive agent, in refractory lupus nephritis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Consecutive consenting patients with refractory lupus nephritis despite steroids plus either cyclophosphamide, mycophenolate or azathioprine were enrolled in this ethics\u2010approved, open\u2010label, prospective study. After baseline assessment, patients received one intravenous infusion of 375\u2009mg\/m<jats:sup>2<\/jats:sup> rituximab. Clinical, biochemical and serological (<jats:styled-content style=\"fixed-case\">DsDNA<\/jats:styled-content>, complement) responses to this dose were analysed. Complete renal response (<jats:styled-content style=\"fixed-case\">CR<\/jats:styled-content>) was defined as normalisation of creatinine, albumin, proteinuria and urinary <jats:styled-content style=\"fixed-case\">RBCs<\/jats:styled-content> and partial response (<jats:styled-content style=\"fixed-case\">PR<\/jats:styled-content>) as \u226550% improvement in at least one parameter, without deterioration in others. B\u2010cell depletion was defined as peripheral <jats:styled-content style=\"fixed-case\">CD19<\/jats:styled-content> lymphocyte count \u22640.05\u2009\u00d7\u200910<jats:sup>9<\/jats:sup>\/L.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Fourteen patients were enrolled in the study. All were B\u2010cell\u2010depleted until 8 months post\u2010dose. Eleven patients (79%) responded (<jats:styled-content style=\"fixed-case\">2CR<\/jats:styled-content>, <jats:styled-content style=\"fixed-case\">9PR<\/jats:styled-content>) at a median time of 5 months, with a 6\u2010month probability of renal response of 43%. Five patients (45%) relapsed at a median time of 17 months. <jats:styled-content style=\"fixed-case\">DsDNA<\/jats:styled-content> titres decreased in 69%. Side\u2010effects were minimal.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Single\u2010dose rituximab is effective in relapsed\/refractory lupus nephritis. Longevity of B\u2010cell depletion with single\u2010dose rituximab is similar to that of four doses with potentially fewer side\u2010effects.<\/jats:p><\/jats:sec>","DOI":"10.1111\/imj.13136","type":"journal-article","created":{"date-parts":[[2016,5,31]],"date-time":"2016-05-31T06:26:52Z","timestamp":1464676012000},"page":"899-901","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Single\u2010dose rituximab in refractory lupus nephritis"],"prefix":"10.1111","volume":"46","author":[{"given":"P.","family":"Kotagiri","sequence":"first","affiliation":[{"name":"Department of Nephrology The Royal Melbourne Hospital  Melbourne Victoria Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Martin","sequence":"additional","affiliation":[{"name":"Department of Nephrology The Royal Melbourne Hospital  Melbourne Victoria Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Hughes","sequence":"additional","affiliation":[{"name":"Department of Nephrology The Royal Melbourne Hospital  Melbourne Victoria Australia"},{"name":"Department of Medicine University of Melbourne  Melbourne Victoria Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Becker","sequence":"additional","affiliation":[{"name":"Department of Nephrology The Royal Melbourne Hospital  Melbourne Victoria Australia"},{"name":"Department of Medicine University of Melbourne  Melbourne Victoria Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Nicholls","sequence":"additional","affiliation":[{"name":"Department of Nephrology The Royal Melbourne Hospital  Melbourne Victoria Australia"},{"name":"Department of Medicine University of Melbourne  Melbourne Victoria Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,8,23]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.34362"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2008101028"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.27233"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.34359"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V84.8.2457.2457"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.3109\/14397595.2015.1060665"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfs285"},{"key":"e_1_2_6_9_1","first-page":"449","article-title":"Efficacy and safety of off\u2010label use of rituximab in refractory lupus: data from the Italian Multicentre Registry","volume":"33","author":"Iaccarino L","year":"2015","journal-title":"Clin Exp Rheumatol"}],"container-title":["Internal Medicine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fimj.13136","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/imj.13136","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T18:24:34Z","timestamp":1696271074000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/imj.13136"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":8,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["10.1111\/imj.13136"],"URL":"https:\/\/doi.org\/10.1111\/imj.13136","archive":["Portico"],"relation":{},"ISSN":["1444-0903","1445-5994"],"issn-type":[{"value":"1444-0903","type":"print"},{"value":"1445-5994","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"2016-01-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-05-22","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-08-23","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}